Boston Scientific Corporation (NYSE:BSX) Shares Sold by Calamos Wealth Management LLC

Calamos Wealth Management LLC decreased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 36.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 98,922 shares of the medical equipment provider's stock after selling 56,510 shares during the quarter. Calamos Wealth Management LLC's holdings in Boston Scientific were worth $9,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in BSX. Bank Pictet & Cie Europe AG increased its position in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Oppenheimer & Co. Inc. increased its holdings in shares of Boston Scientific by 18.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock worth $3,987,000 after buying an additional 6,264 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Boston Scientific by 13.0% in the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock worth $504,000 after buying an additional 575 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its holdings in shares of Boston Scientific by 109.9% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider's stock worth $24,126,000 after buying an additional 141,398 shares during the last quarter. Finally, Little House Capital LLC bought a new stake in Boston Scientific during the first quarter worth approximately $945,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Up 0.6%

Boston Scientific stock traded up $0.67 during trading hours on Friday, reaching $104.30. The stock had a trading volume of 2,931,148 shares, compared to its average volume of 6,666,246. The company has a market cap of $154.30 billion, a price-to-earnings ratio of 76.13, a PEG ratio of 2.71 and a beta of 0.68. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. The business's 50 day moving average price is $103.42 and its 200-day moving average price is $100.14. Boston Scientific Corporation has a 52 week low of $71.88 and a 52 week high of $107.53.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. Boston Scientific's revenue was up 20.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.56 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the transaction, the executive vice president owned 22,235 shares in the company, valued at $2,269,304.10. This represents a 43.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the transaction, the chief executive officer owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 461,970 shares of company stock worth $47,755,193 over the last ninety days. Corporate insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on BSX shares. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Citigroup reaffirmed a "buy" rating and set a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Barclays increased their target price on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Evercore ISI lifted their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Finally, Morgan Stanley increased their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. Twenty-two research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $116.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.